Cetera Investment Advisers Sells 906 Shares of GRAIL, Inc. $GRAL

Cetera Investment Advisers decreased its position in shares of GRAIL, Inc. (NASDAQ:GRAL) by 5.2% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 16,508 shares of the company’s stock after selling 906 shares during the quarter. Cetera Investment Advisers’ holdings in GRAIL were worth $422,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the company. Wells Fargo & Company MN acquired a new stake in shares of GRAIL during the 4th quarter worth approximately $90,000. Alliancebernstein L.P. acquired a new stake in shares of GRAIL during the 4th quarter worth approximately $250,000. GAMMA Investing LLC grew its position in shares of GRAIL by 4,102.5% during the 1st quarter. GAMMA Investing LLC now owns 25,131 shares of the company’s stock worth $642,000 after buying an additional 24,533 shares during the period. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of GRAIL during the 1st quarter worth approximately $719,000. Finally, Deutsche Bank AG bought a new position in shares of GRAIL in the 4th quarter worth $1,001,000.

GRAIL Stock Performance

Shares of GRAL opened at $32.43 on Monday. The business has a 50-day moving average of $40.12 and a 200 day moving average of $36.33. GRAIL, Inc. has a fifty-two week low of $12.33 and a fifty-two week high of $63.99. The firm has a market cap of $1.17 billion, a P/E ratio of -2.47 and a beta of 3.26.

GRAIL (NASDAQ:GRAL) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($3.18) earnings per share for the quarter, missing the consensus estimate of ($3.14) by ($0.04). The firm had revenue of $35.54 million during the quarter, compared to analysts’ expectations of $37.57 million. GRAIL had a negative return on equity of 16.64% and a negative net margin of 329.86%. As a group, research analysts predict that GRAIL, Inc. will post -15.15 earnings per share for the current fiscal year.

Insider Activity

In other news, President Joshua J. Ofman sold 9,692 shares of GRAIL stock in a transaction dated Monday, June 30th. The stock was sold at an average price of $52.00, for a total transaction of $503,984.00. Following the completion of the sale, the president owned 492,076 shares in the company, valued at approximately $25,587,952. This trade represents a 1.93% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Chun R. Ding sold 339,800 shares of GRAIL stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $49.53, for a total value of $16,830,294.00. Following the sale, the insider owned 3,305,055 shares of the company’s stock, valued at approximately $163,699,374.15. This trade represents a 9.32% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 357,492 shares of company stock worth $17,645,718.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group increased their target price on GRAIL from $32.00 to $43.00 and gave the stock a “buy” rating in a report on Wednesday, May 14th.

GRAIL Profile

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.